论文部分内容阅读
洛赛克(Omeprazole,Ome)是新近应用于临床治疗消化性溃疡(PU)的新药,通过选择性地抑制胃壁细胞中质子泵即H~+-K~+-ATP酶而产生强力的抑制胃酸分泌作用,从而加速PU的愈合。本文作者采用随机临床对照试验(RCT)对比观察了Ome与二、三代H_2-受体拮抗剂雷尼替丁(Ran)及法莫替丁(Fam)对十二指肠溃疡(Duodenal Ulcer,DU)的近期疗效。材料和方法 1990年10月——1992年5月,经我院内镜确诊的DU患者142例,同时于胃窦粘膜活检作快速尿素酶实验证实伴有幽门螺旋菌(HP)感染,除外合并严重并发症,心、肝、肾功能不全者及妊娠哺乳期妇女后,随机纳入A、B、C三组、A组:48例,给予Ome20mg1次/日:B组:41例,给予Fam20mg2次/日;C组:
Omeprazole (Ome), a new drug recently used in the clinical treatment of peptic ulcer (PU), produces potent inhibitory effects on gastric acid by selectively inhibiting the proton pump, H ~ + -K ~ + -ATPase, in gastric parietal cells Secretion, thereby accelerating the healing of PU. In this study, randomized controlled trials (RCTs) were used to compare the effects of Ome and ranitidine, a second and third generation H 2 -adrenoceptor, and Fam on duodenal ulcer (DU ) Of the recent effect. MATERIALS AND METHODS: From October 1990 to May 1992, 142 patients with DU confirmed by endoscopy in our hospital were enrolled in this study. A rapid urease test in antral mucosal biopsy was performed to confirm the presence of Helicobacter pylori (HP) infection. Severe complications, heart, liver, renal insufficiency and pregnant women during lactation, were randomly divided into A, B, C three groups, A group: 48 cases, given Ome20mg1 times / day: B group: 41 cases, Fam20mg2 times / Day; Group C: